Cargando…

Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study

BACKGROUND: Obesity has been inconsistently linked to prostate cancer, mainly with mortality rather than incidence. Few large-scale studies exist assessing obesity in relation to prostate-specific antigen (PSA)-detected prostate cancer. METHODS: We used cases and stratum-matched controls from the po...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimitropoulou, P, Martin, R M, Turner, E L, Lane, J A, Gilbert, R, Davis, M, Donovan, J L, Hamdy, F C, Neal, D E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048201/
https://www.ncbi.nlm.nih.gov/pubmed/21266978
http://dx.doi.org/10.1038/sj.bjc.6606066
_version_ 1782199128307007488
author Dimitropoulou, P
Martin, R M
Turner, E L
Lane, J A
Gilbert, R
Davis, M
Donovan, J L
Hamdy, F C
Neal, D E
author_facet Dimitropoulou, P
Martin, R M
Turner, E L
Lane, J A
Gilbert, R
Davis, M
Donovan, J L
Hamdy, F C
Neal, D E
author_sort Dimitropoulou, P
collection PubMed
description BACKGROUND: Obesity has been inconsistently linked to prostate cancer, mainly with mortality rather than incidence. Few large-scale studies exist assessing obesity in relation to prostate-specific antigen (PSA)-detected prostate cancer. METHODS: We used cases and stratum-matched controls from the population-based PSA-testing phase of the Prostate testing for cancer and Treatment study to examine the hypothesis that obesity as measured by body mass index (BMI), waist circumference and waist-to-hip ratio (WHR) is associated with increased prostate cancer risk, and with higher tumour stage and grade. In all, 2167 eligible cases and 11 638 randomly selected eligible controls with PSA values were recruited between 2001 and 2008. A maximum of 960 cases and 4156 controls had measurement data, and also complete data on age and family history, and were included in the final analysis. BMI was categorised as <25.0, 25.0–29.9, ⩾30.0 in kg m(−2). RESULTS: Following adjustment for age and family history of prostate cancer, we found little evidence that BMI was associated with total prostate cancer (odds ratio (OR): 0.83, 95% confidence interval (CI): 0.67, 1.03; highest vs lowest tertile; P-trend 0.1). A weak inverse association was evident for low-grade (OR: 0.76, 95% CI: 0.59, 0.97; highest vs lowest tertile; P-trend 0.045) prostate cancer. We found no association of either waist circumference (OR: 0.94, 95% CI: 0.80, 1.12; highest vs lowest tertile) or waist-to-hip ratio (WHR; OR: 0.93, 95% CI: 0.77, 1.11; highest vs lowest tertile) with total prostate cancer, and in analyses stratified by disease stage (all P-trend>0.35) or grade (all P-trend>0.16). CONCLUSION: General adiposity, as measured by BMI, was associated with a decreased risk of low-grade PSA-detected prostate cancer. However, effects were small and the confidence intervals had limits very close to one. Abdominal obesity (as measured by WHR/waist circumference) was not associated with PSA-detected prostate cancer.
format Text
id pubmed-3048201
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-30482012012-03-01 Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study Dimitropoulou, P Martin, R M Turner, E L Lane, J A Gilbert, R Davis, M Donovan, J L Hamdy, F C Neal, D E Br J Cancer Epidemiology BACKGROUND: Obesity has been inconsistently linked to prostate cancer, mainly with mortality rather than incidence. Few large-scale studies exist assessing obesity in relation to prostate-specific antigen (PSA)-detected prostate cancer. METHODS: We used cases and stratum-matched controls from the population-based PSA-testing phase of the Prostate testing for cancer and Treatment study to examine the hypothesis that obesity as measured by body mass index (BMI), waist circumference and waist-to-hip ratio (WHR) is associated with increased prostate cancer risk, and with higher tumour stage and grade. In all, 2167 eligible cases and 11 638 randomly selected eligible controls with PSA values were recruited between 2001 and 2008. A maximum of 960 cases and 4156 controls had measurement data, and also complete data on age and family history, and were included in the final analysis. BMI was categorised as <25.0, 25.0–29.9, ⩾30.0 in kg m(−2). RESULTS: Following adjustment for age and family history of prostate cancer, we found little evidence that BMI was associated with total prostate cancer (odds ratio (OR): 0.83, 95% confidence interval (CI): 0.67, 1.03; highest vs lowest tertile; P-trend 0.1). A weak inverse association was evident for low-grade (OR: 0.76, 95% CI: 0.59, 0.97; highest vs lowest tertile; P-trend 0.045) prostate cancer. We found no association of either waist circumference (OR: 0.94, 95% CI: 0.80, 1.12; highest vs lowest tertile) or waist-to-hip ratio (WHR; OR: 0.93, 95% CI: 0.77, 1.11; highest vs lowest tertile) with total prostate cancer, and in analyses stratified by disease stage (all P-trend>0.35) or grade (all P-trend>0.16). CONCLUSION: General adiposity, as measured by BMI, was associated with a decreased risk of low-grade PSA-detected prostate cancer. However, effects were small and the confidence intervals had limits very close to one. Abdominal obesity (as measured by WHR/waist circumference) was not associated with PSA-detected prostate cancer. Nature Publishing Group 2011-03-01 2011-01-25 /pmc/articles/PMC3048201/ /pubmed/21266978 http://dx.doi.org/10.1038/sj.bjc.6606066 Text en Copyright © 2011 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Epidemiology
Dimitropoulou, P
Martin, R M
Turner, E L
Lane, J A
Gilbert, R
Davis, M
Donovan, J L
Hamdy, F C
Neal, D E
Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study
title Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study
title_full Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study
title_fullStr Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study
title_full_unstemmed Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study
title_short Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study
title_sort association of obesity with prostate cancer: a case-control study within the population-based psa testing phase of the protect study
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048201/
https://www.ncbi.nlm.nih.gov/pubmed/21266978
http://dx.doi.org/10.1038/sj.bjc.6606066
work_keys_str_mv AT dimitropouloup associationofobesitywithprostatecanceracasecontrolstudywithinthepopulationbasedpsatestingphaseoftheprotectstudy
AT martinrm associationofobesitywithprostatecanceracasecontrolstudywithinthepopulationbasedpsatestingphaseoftheprotectstudy
AT turnerel associationofobesitywithprostatecanceracasecontrolstudywithinthepopulationbasedpsatestingphaseoftheprotectstudy
AT laneja associationofobesitywithprostatecanceracasecontrolstudywithinthepopulationbasedpsatestingphaseoftheprotectstudy
AT gilbertr associationofobesitywithprostatecanceracasecontrolstudywithinthepopulationbasedpsatestingphaseoftheprotectstudy
AT davism associationofobesitywithprostatecanceracasecontrolstudywithinthepopulationbasedpsatestingphaseoftheprotectstudy
AT donovanjl associationofobesitywithprostatecanceracasecontrolstudywithinthepopulationbasedpsatestingphaseoftheprotectstudy
AT hamdyfc associationofobesitywithprostatecanceracasecontrolstudywithinthepopulationbasedpsatestingphaseoftheprotectstudy
AT nealde associationofobesitywithprostatecanceracasecontrolstudywithinthepopulationbasedpsatestingphaseoftheprotectstudy